Protagonist Therapeutics Inc (PTGX)

[TheFinalCD]

this is crazy, crashed to 4.47 on bad data, then almost total recovery after bunch of insider buying filings come out after hours


Protagonist Therapeutics Inc (NASDAQ: PTGX)(announced results from mid-stage study of PTG-300 in transfusion-dependent beta-thalassemia)

this is very unusual to see this type of recovery that fast

is there any other news or catalyst that would support this up here?

$PTGX

[Actualfactual]

Nice. Happy trading

[keekee]

Bought back.most under $7. I brought in my shorts to.lower it for.me. So I grabbed back what I sold above $8. Still going to.$9. I'll just make more money on it
Lol

[Actualfactual]

Just scalped it again. Made some great money here. Hope you did too

[keekee]

Cash out at $9 and I already have candi6to put the cash in for another monster performance. LOL

[keekee]

My first entry was 500 @ $4.74 AH yesterday. Then when the form 4s hit, I took a couple of thousands at $5.08 and $5.15. Then bought more at $5.25 permit today. What a gift !!!

[Actualfactual]

I had 5k shares under $5. I just sold seconds before the halt..glta

[keekee]

Been loading since premarket at$5.25. Will hold till $9

[Actualfactual]

This looks great for a bounce for tomorrow.

[ClayTrader]

* * $PTGX Video Chart 12-03-2019 * *

Link to Video - click here to watch the technical chart video

[ClayTrader]

* * $PTGX Video Chart 06-07-2019 * *

Link to Video - click here to watch the technical chart video

[north40000]

https://ih.advfn.com/stock-market/NASDAQ/protagonist-therapeutics-inc-PTGX/stock-news/79907251/oral-alpha-4-beta-7-integrin-antagonist-pn-943-dem

[Hikiro]

Tomorrow it going to be crazy!!! Great gains today!

[MinnieM]

$PTGX - For those wondering why it tanked today:

Protagonist Therapeutics Discontinues Phase 2b PROPEL Trial of PTG-100 for the Treatment of Ulcerative Colitis following Interim Analysis
https://www.prnewswire.com/news-releases/protagonist-therapeutics-discontinues-phase-2b-propel-trial-of-ptg-100-for-the-treatment-of-ulcerative-colitis-following-interim-analysis-300619191.html

Protagonist Therapeutics, Inc. (Nasdaq: PTGX) today announced that the Company is discontinuing the Phase 2b PROPEL study of PTG-100, its investigational oral GI-restricted alpha-4-beta-7 integrin antagonist peptide, in patients with moderate to severe ulcerative colitis (UC). This decision followed a planned interim analysis by an independent Data Monitoring Committee (DMC) of unblinded efficacy and safety data from the first 65 patients from the ongoing 240 patient trial who had completed the 12 week treatment with PTG-100. Using pre-specified criteria, the DMC deemed the trial to be futile based on an analysis of the primary endpoint of clinical remission. No safety concerns were noted in the analysis.

[Ad719]

http://www.thecerbatgem.com/2016/09/15/protagonist-therapeutics-incs-quiet-period-will-expire-on-september-20th-nasdaqptgx.html

[fredugsi]

Big day today based on (2) hedge funds buying large percentages (9.7% and 6.8%) of the stock. So minimum of 16%+ of the stock "locked up"

[mfreddy08]

Lol...scottrade shows bid at .01 and ask at $199,999.99 hahaha

[mfreddy08]

Lol...scottrade shows bid at .01 and ask at $199,999.99 hahaha

[protagonist12]

Protagonist Therapeutics, which is developing peptide-based oral drugs for inflammatory bowel disease, raised $90 million by offering 7.5 million shares at $12, within the range of $11 to $13. The company had originally planned to raise $70 million by offering 5.84 million shares. Insiders had indicated on buying up to $40 million of the IPO. Protagonist Therapeutics plans to list on the Nasdaq under the symbol PTGX. Leerink Partners, Barclays and BMO Capital Markets acted as lead managers on the deal.